WO2020044067A1 - Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects - Google Patents
Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects Download PDFInfo
- Publication number
- WO2020044067A1 WO2020044067A1 PCT/HU2019/000033 HU2019000033W WO2020044067A1 WO 2020044067 A1 WO2020044067 A1 WO 2020044067A1 HU 2019000033 W HU2019000033 W HU 2019000033W WO 2020044067 A1 WO2020044067 A1 WO 2020044067A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- general formula
- beta
- nitrogen atom
- pharmaceutical combination
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 32
- 239000002876 beta blocker Substances 0.000 title claims abstract description 20
- 239000002253 acid Substances 0.000 claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 230000002829 reductive effect Effects 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- -1 methipranolol Chemical compound 0.000 claims description 8
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 230000000144 pharmacologic effect Effects 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229960002781 bisoprolol Drugs 0.000 claims description 4
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical group N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 claims description 3
- 208000010496 Heart Arrest Diseases 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 208000010428 Muscle Weakness Diseases 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 230000036471 bradycardia Effects 0.000 claims description 3
- 208000006218 bradycardia Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 208000002173 dizziness Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000036543 hypotension Effects 0.000 claims description 3
- 229960002237 metoprolol Drugs 0.000 claims description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 claims description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 2
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 229960002122 acebutolol Drugs 0.000 claims description 2
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- 229960004324 betaxolol Drugs 0.000 claims description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 229960001222 carteolol Drugs 0.000 claims description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004195 carvedilol Drugs 0.000 claims description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002320 celiprolol Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229960003745 esmolol Drugs 0.000 claims description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 229960001632 labetalol Drugs 0.000 claims description 2
- 229960000831 levobunolol Drugs 0.000 claims description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 2
- 229910052751 metal Chemical class 0.000 claims description 2
- 239000002184 metal Chemical class 0.000 claims description 2
- NMOVJBAGBXIKCG-UHFFFAOYSA-N n-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidoyl chloride Chemical compound C1CCCCN1CC(O)CON=C(Cl)C1=CC=CN=C1 NMOVJBAGBXIKCG-UHFFFAOYSA-N 0.000 claims description 2
- 229960004255 nadolol Drugs 0.000 claims description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 2
- 229960000619 nebivolol Drugs 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229960004570 oxprenolol Drugs 0.000 claims description 2
- 229960002035 penbutolol Drugs 0.000 claims description 2
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 claims description 2
- 229960002508 pindolol Drugs 0.000 claims description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003712 propranolol Drugs 0.000 claims description 2
- 229960002370 sotalol Drugs 0.000 claims description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
- HBJUQLMVCIEESP-UHFFFAOYSA-N 2,5-dihydro-1,2,4-oxadiazole Chemical group C1NC=NO1 HBJUQLMVCIEESP-UHFFFAOYSA-N 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
- 108010048829 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Proteins 0.000 claims 1
- 102000009453 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Human genes 0.000 claims 1
- 229930016911 cinnamic acid Natural products 0.000 claims 1
- 235000013985 cinnamic acid Nutrition 0.000 claims 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000004526 pharmaceutical effect Effects 0.000 abstract 2
- 235000013350 formula milk Nutrition 0.000 description 38
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 description 20
- 238000011282 treatment Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- NMOVJBAGBXIKCG-VKAVYKQESA-N (3z)-n-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidoyl chloride Chemical compound C1CCCCN1CC(O)CO\N=C(/Cl)C1=CC=CN=C1 NMOVJBAGBXIKCG-VKAVYKQESA-N 0.000 description 9
- 229950002409 bimoclomol Drugs 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- SGEIEGAXKLMUIZ-ZPTIMJQQSA-N (3e)-n-[(2r)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride Chemical compound C([C@H](O)CN1CCCCC1)O\N=C(\Cl)C1=CC=C[N+]([O-])=C1 SGEIEGAXKLMUIZ-ZPTIMJQQSA-N 0.000 description 8
- 229950011582 arimoclomol Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229950004636 iroxanadine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- TWUSDDMONZULSC-QMTHXVAHSA-N (1s,2r)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@H](O)[C@@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-QMTHXVAHSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IGMZDGBNMCELOE-UHFFFAOYSA-N 1-chloro-3-piperidin-1-ylpropan-2-ol Chemical compound ClCC(O)CN1CCCCC1 IGMZDGBNMCELOE-UHFFFAOYSA-N 0.000 description 1
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QXIUMMLTJVHILT-UHFFFAOYSA-N 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=C1C=C(C#N)N2 QXIUMMLTJVHILT-UHFFFAOYSA-N 0.000 description 1
- BBMFSGOFUHEVNP-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC(O)=CC=C1C(O)=O BBMFSGOFUHEVNP-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 101710190843 Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
- 208000033149 Farber disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 206010072927 Mucolipidosis type I Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229950005341 bucindolol Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 201000008977 glycoproteinosis Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229950005241 landiolol Drugs 0.000 description 1
- WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000011985 sialidosis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a pharmaceutical combination, which has reduced side effects.
- the pharmaceutical combination of the invention consists of a first pharma- ceutical composition containing a beta-receptor blocker as active ingredient, and a second pharma- ceutical composition containing a hydroximic-acid derivative as active ingredient.
- Beta-receptor blockers or beta-receptor antagonists are widely used active pharmaceutical in gredients primarily for the treatment of hypertension, heart failure and certain cardiac arrhythmias. [Frishman, W.H.: beta-Adrenergic blockers: a 50-year hystorical perspective, Am. J. Ther., 15(6), 565-76 (2008)]. These active ingredients act on beta-adrenergic receptors, preventing the adrenaline and noradrenaline from binding to the receptors.
- beta-receptor blockers is limited by their certain unwanted effects, including their cardiovascular side effects or exacerbation of asthma. Car diovascular side effects may include bradycardia, hypotension, heart failure, cardiac arrest, dizziness, muscle weakness and fatigue due to decreased blood circulation. Peripheral vasoconstrictor effect may also occur.
- a pharmaceutical preparation of the invention comprising a first pharmaceutical preparation comprising a beta-blocker as an active ingre transducer and a second pharmaceutical preparation containing as an active ingredient a hydroximic-acid derivative of the general formula I
- Ar is pyridyl
- A is a valence bond
- X is -NH 2
- R is a group of the general formula
- Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or b) Ar is pyridyl-,
- A is a valence bond
- X is -halogen
- R is a group of the general formula
- Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or its N- oxide, or
- Ar is pyridyl
- A is a valence bond
- X is a group of the general formula
- Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom
- R taken together with Y form a valence bond between the nitrogen atom adjacent to R and the carbon atom adjacent to Y to form a six-membered oxadiazine ring, or
- Ar is phenyl
- X is a group of the general formula
- Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom.
- R is a hydroxyl group
- X is a group of the general formula
- the first pharmaceutical composition comprising a beta-receptor blocker used as an ingredient in the pharmaceutical combination of the present invention comprises, for example, one of the fol- lowing:
- acebutolol alprenolol, atenolol, betaxolol, bisoprolol, bucindolol, butoxamine, carteolol, carvedilol, celiprolol, cyanopindolol, esmolol, labetalol, landiolol, levobunolol, methipranolol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, or, if chemically possible, a pharmaceutically acceptable acid addition salt or a metal salt of the active ingredients listed.
- the metoprolol is used in the form of its tartrate or succinate.
- a preferred beta-receptor blocking agent is the bisoprolol.
- the active ingredient of the pharmaceutical composition used as another component of the pharmaceutical combination according to the invention is a hydroximic-acid derivative of general formula I or a pharmaceutically acceptable acid addition salt thereof.
- Ar When Ar is pyridyl, it is 2-, 3- or 4-pyridyl.
- a 5- to 7-membered saturated heterocyclic group containing one ni- trogen atom, formulated in Ri is defined as pyrrolidyl, piperidyl or hexamethyleneimino.
- the pyrrolidyl, piperidyl or hexamethyleneimino group is attached via its nitrogen atom to the carbon atom adjacent to Ri.
- the N-oxide of the compound of general formula I as defined in (b) above is understood to mean the N-oxide formed on the nitrogen atom of the pyridyl group according to the meaning of Ar, and / or the N-oxide, which is formed on the nitrogen atom present in the 5-7 membered saturated heterocyclic group according to the meaning of Ri.
- Pharmaceutically acceptable acid addition salt is an acid addition salt formed with a pharma- ceutically acceptable inorganic or organic acid, such as hydrochloride, acetate, fumarate, maleate, etc.
- Compounds of general formula I, wherein in the formula A is a group of formula -CH CH-, may have additional geometric isomers too.
- Corn- pounds of general formula I generally have a chiral centre as well, so that their optically active iso- mers R and S are also possible.
- any compound of general formula I is understood to include their geometric and/or optical isomers as well and an optional mixture of isomers.
- a preferred subgroup (a) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (a) above.
- a particularly preferred compound in this subgroup is the 0-(3- piperidino-2-hydroxy-l-propyl)-nicotinic acid amidoxime (abbreviated as BGP-15), which is expe- trans used in the form of its dihydrochloride of formula II:
- a preferred subgroup (a) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (b) above.
- a particularly preferred compound in this subgroup is the N-[2- hydroxy-3-(l -piperidinyl)propoxy]pyridine-3-carboximidoyl chloride (bimoclomol) III or one of its N-oxides, N-[2-hydroxy-3-(l-piperidinyl)-propoxy]-pyridine-l-oxide-3-carboximidoyl chloride (arimoclomol) of formula IV
- a preferred subgroup (c) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (c) above.
- a particularly preferred compound in this subgroup is 5-(piperidin- l-ylmethyl)-3-(pyridin-3-yl)-5,6-dihydro-2H-l,2,4-oxadiazine (iroxanadine)
- a preferred subgroup (d) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (d) above.
- a particularly preferred compound in this subgroup is the N-[3- (hexamethyleneimino)-2-hydroxypropyl]-cinnamic acid amidoxime of the formula (VI), (di) above (abbreviated as NG-094).
- hydroximic-acid derivatives of formula I are known compounds.
- amidoxime derivatives of formula I wherein Ar, A, X, and R are as defined in (a) above, may be prepared by the process described in U.S. Patent No. 4,187,220.
- hydroximic-acid derivatives of formula I according to (a) above generally have PARP inhibitory activity. Among them, many of the pharmacological effects of BGP-15 of formula II are known.
- U.S. Patent No. 6,306,878 relates to a method for protecting the mitochondrial genome and / or mitochondria from damage leading to myopathies and neurodegenerative diseases by administer ing an effective, non-toxic dose of a hydroximic-acid derivative, such as BGP-15, to a patient sus ceptible to such damage.
- a hydroximic-acid derivative such as BGP-15
- U.S. Pat. No. 6,458,37l relates to a formulation containing as active ingredient 0.1-30% of a hydroximic-acid derivative, such as BGP-15 and a carrier, which is capable of reducing the occur rence of light damage caused by UV-B radiation.
- U.S. Patent No. 6,884,424 relates to a method for inhibiting actinic keratosis by applying a hydroximic-acid derivative, such as BGP-15, to the affected skin.
- a hydroximic-acid derivative such as BGP-15
- U.S. Patent No. 6,451,851 relates to a method for treating a patient suffering from a viral infection by treating the patient with a therapeutically effective amount of a known antiviral agent and a hydroximic-acid derivative such as BGP-15.
- U.S. Patent No. 6,440,998 relates to a pharmaceutical composition having a reduced side ef- fect having an antitumor effect comprising cisplatin or carboplatin and a hydroximic-acid derivative such as BGP-15.
- U.S. Patent No. 6,656,955 relates to a pharmaceutical composition having a reduced side effect having an anticancer effect comprising paclitaxel or docetaxel and a hydroximic-acid de- rivative such as BGP-15.
- U.S. Patent No. 6,720,337 relates to a pharmaceutical composition having WO 2020/044067 . . . . . , .
- PCT/HU2019/000033 a reduced side effect having an anti cancer effect comprising oxaliplatm and a hyaroximic-ac deriv ative such as BGP-15.
- U.S. Patent No. 6,838,469 relates to a pharmaceutical composition having a reduced side effect having an antitumor effect, comprising pyrimidine derivatives and BGP-15.
- PCT Patent Application published under No. WO 00/07580 discloses experimental data on the antidiabetic effect of BGP-15 in the treatment of type 1 diabetes.
- WO 03/007951 relates to a pharmaceutical combination of hydroximic-acid derivatives such as BGP-1 and an antidiabetic or antihyperlipidemic agent for the prevention or treatment of pre-diabetes, metabolic X-syndrome or diabetes, and disorders associ ated with these conditions, such as endogenous metabolic disorders, insulin resistance, dyslipidae- mia, baldness, diffuse effluvium, and / or female endocrine disorders based on androgen overweight.
- hydroximic-acid derivatives such as BGP-1
- an antidiabetic or antihyperlipidemic agent for the prevention or treatment of pre-diabetes, metabolic X-syndrome or diabetes, and disorders associ ated with these conditions, such as endogenous Heights, insulin resistance, dyslipidae- mia, baldness, diffuse effluvium, and / or female endocrine disorders based on androgen overweight.
- PCT Application published under No. WO 2005/122678 relates to the use of BGP-15 in a pharmaceutical composition having prokinetic activity (i.e., inducing activity in the stomach and in testines).
- PCT Application published under No. WO 2005/123049 relates to the use of BGP-15 for mi tochondrial genesis, that is, to increase the number of mitochondria present in cells, resulting in a robotizing effect.
- European Patent No. 2,089,031 discloses that BGP-15 can be used to reduce overweight or obesity.
- European Patent No. 2,089,032 discloses that BGP-15 reduces the side effects of known anti- psychotics, antidepressants and antiepileptics leading to overweight or obesity.
- BGP-15 can be used to reduce adverse psychiatric side effects of cannabinoid CBi receptor antagonists, such as ri- monabant.
- BGP-15 may be used for the prevention and / or treatment of muscle atrophy.
- BGP-15 can be used to improve the tissue regeneration effect of adult stem cells, to promote the survival, adhesion, and regulation of adult stem cells.
- bimoclomol of formula III according to (b) above is described in International Patent Application published under No. WO 90/04584.
- the bimoclomol appli cable in the treatment of diabetic angiopathy can be prepared by reacting 3-pyridyl aldoxime with 3- piperidino-2-hydroxy-l-chloropropane, then by the chlorination of the obtained 0-(3-piperidino-2- hydroxy-l -propyl) with thionyl chloride.
- the expres- sion or activity of molecular chaperones is enhanced by the use of various compounds, including bimoclomol.
- the compound may be used in the treat- ment of pathological conditions related to cell membranes or cellular organelles such as diabetes mellitus, diseases associated with mitochondrial damage, diseases of toxic origin, cardiovascular, vascular, allergic diseases, immune and autoimmune diseases, viral infections, bacterial infections, tumorous diseases, skin diseases, diseases caused by physiological stress.
- bimo- clomol and arimoclomol can be used to increase the intracellular concentration and / or activity of Hsp 70 in a lysosomal storage disease, such as for the treatment of Niemann-Pick disease, Gaucher disease, Farber disease, Rrabbe disease, Fabbre disease, or sialidosis.
- bimo- clomol and arimoclomol can be used to improve the tissue regeneration effect of adult stem cells, to promote stem cell survival, adhesion and differentiation.
- hydroxy acid derivatives of formula I according to (d) above may be prepared according to the methods described in PCT Application Published under No. WO 01/70674.
- the compounds are useful in the treatment of conditions deficient in oxygen and / or energy, diseases based on PARP inhibition, diseases of viral origin or diseases caused by toxic effects.
- the compounds are also disclosed in the aforementioned PCT Patent Applications published under Nos. WO 2013/02431 1 and WO 2013/024312.
- compositions are understood to mean the follow- ing compositions:
- each separate pharmaceutical composition is administered simultaneously or sequen tially to the patient who is in need of the treatment;
- a pharmaceutical composition comprising the beta-blocking agent and a hydroximic-acid de rivative of formula I and a pharmaceutically acceptable carrier at the same time, wherein either a mixture of the two agents is present, or each is present in a different location in the pharmaceutical composition, e.g. in the tablet core and the other in the tablet core coating.
- any conventional carrier and any conventional pharmaceutical preparation proce dure may be used to prepare the individual pharmaceutical compositions or the single pharmaceutical composition.
- the pharmaceutical combination may be any dosage form suitable for oral, parenteral or rectal administration or topical administration, or solid or liquid form.
- the weight ratio of active ingredients in the pharmaceutical combination is generally (1-1000) : ( 1000- 1 ) .
- the pharmaceutical combination of the invention may contain more than one beta- receptor blocking agent.
- Solid pharmaceutical compositions suitable for oral administration may be in the form of powders, capsules, tablets, film-coated tablets, microcapsules, sustained-release formulations, etc., and may contain binding agents as carriers, such as gelatine, sorbitol, polyvinylpyrrolidone, etc.; fillers such as lactose, glucose, starch, calcium phosphate, etc.; tabletting aids such as magnesium stearate, talc, polyethylene glycol, silica, etc.; wetting agents such as sodium lauryl sulphate, etc.
- binding agents as carriers, such as gelatine, sorbitol, polyvinylpyrrolidone, etc.
- fillers such as lactose, glucose, starch, calcium phosphate, etc.
- tabletting aids such as magnesium stearate, talc, polyethylene glycol, silica, etc.
- wetting agents such as sodium lauryl sulphate, etc.
- Liquid pharmaceutical preparations for oral administration may be in the form of solutions, suspensions or emulsions and may include as carriers, for example, suspending agents, such as gela- tine, carboxymethylcellulose, etc.; emulsifiers such as sorbitan monooleate, etc.; solvents such as water, oils, glycerol, propylene glycol, ethanol, etc.; preservatives such as methyl p-hydroxybenzoic acid, etc.
- suspending agents such as gela- tine, carboxymethylcellulose, etc.
- emulsifiers such as sorbitan monooleate, etc.
- solvents such as water, oils, glycerol, propylene glycol, ethanol, etc.
- preservatives such as methyl p-hydroxybenzoic acid, etc.
- compositions for parenteral administration are generally sterile solutions of the active compounds.
- the drug combination will generally contain a unit dose of the active ingredients.
- the daily dose may be administered in one or more portions.
- the actual dose will depend on many factors and will be determined by the doctor.
- composition (s) forming the pharmaceutical combination of the present invention may be prepared in a manner known in the art (e.g., Remington's Pharmaceutical Sciences mentioned above).
- the present invention relates to the use of a hydroximic-acid derivative of the Formula I or a pharmaceutically acceptable acid addition salt thereof for reducing one or more side effects of a beta- receptor blocking drug, wherein the side effects include particularly cardiovascular side effects such as bradycardia, hypotension, heart failure, cardiac arrest, dizziness, muscle weakness, fatigue, periph eral vasoconstrictor effect, etc. or aggravation of asthma.
- cardiovascular side effects such as bradycardia, hypotension, heart failure, cardiac arrest, dizziness, muscle weakness, fatigue, periph eral vasoconstrictor effect, etc. or aggravation of asthma.
- a pharmaceutical preparation having a beta-receptor blocking active ingredient is administered also a hydroximic-acid derivative of formula I or a phar maceutically acceptable acid addition salt thereof, preferably in the form of a pharmaceutical prepa ration.
- the two active substances may be administered simultaneously or sequentially.
- the active ingredient may be present in separate pharmaceutical preparations or in a single pharmaceutical preparation, as described above.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical combination, which modifies the pharmaceutical effect of the beta-receptor blockers, has new pharmaceutical effects and reduced side effects. More particularly, the pharmaceutical combination of the invention consists of a first pharmaceutical composition containing a beta-receptor blocker as active ingredient, and a second pharmaceutical composition containing a hydroximic-acid derivative as active ingredient. An object of the present invention is to improve the therapeutic effect of beta-receptor blockers.
Description
Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects
The invention relates to a pharmaceutical combination, which has reduced side effects.
More particularly, the pharmaceutical combination of the invention consists of a first pharma- ceutical composition containing a beta-receptor blocker as active ingredient, and a second pharma- ceutical composition containing a hydroximic-acid derivative as active ingredient.
Beta-receptor blockers or beta-receptor antagonists are widely used active pharmaceutical in gredients primarily for the treatment of hypertension, heart failure and certain cardiac arrhythmias. [Frishman, W.H.: beta-Adrenergic blockers: a 50-year hystorical perspective, Am. J. Ther., 15(6), 565-76 (2008)]. These active ingredients act on beta-adrenergic receptors, preventing the adrenaline and noradrenaline from binding to the receptors. The use of beta-receptor blockers is limited by their certain unwanted effects, including their cardiovascular side effects or exacerbation of asthma. Car diovascular side effects may include bradycardia, hypotension, heart failure, cardiac arrest, dizziness, muscle weakness and fatigue due to decreased blood circulation. Peripheral vasoconstrictor effect may also occur.
It is an object of the present invention to modify the activity of beta-receptor blockers, to induce new pharmacological effects, and to reduce side effects and thereby improve their therapeutic use.
It has now been found that this object is achieved by a pharmaceutical preparation of the invention comprising a first pharmaceutical preparation comprising a beta-blocker as an active ingre dient and a second pharmaceutical preparation containing as an active ingredient a hydroximic-acid derivative of the general formula I
I
or a pharmaceutically acceptable acid addition salt thereof.
In general formula I
a) Ar is pyridyl,
A is a valence bond,
X is -NH2,
R is a group of the general formula
OH
— O— CH2— CH— CH2— Ri
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or b) Ar is pyridyl-,
A is a valence bond,
X is -halogen,
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or its N- oxide, or
c) Ar is pyridyl,
A is a valence bond,
X is a group of the general formula
Y
-NH— O— CH2— CH— CH2— Ri wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom,
R taken together with Y form a valence bond between the nitrogen atom adjacent to R and the carbon atom adjacent to Y to form a six-membered oxadiazine ring, or
d) Ar is phenyl,
A is -CH = CH-, and
di) X is a group of the general formula
OH
-NH— CH2— CH— CH2— Ri
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom.
R is a hydroxyl group, or
d2) X is a group of the general formula
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, Y’ taken together with R form a valence bond between the oxygen adjacent to Y’ and the nitrogen adjacent to R to form a five-membered l,2,4-oxadiazoline ring.
The first pharmaceutical composition comprising a beta-receptor blocker used as an ingredient in the pharmaceutical combination of the present invention comprises, for example, one of the fol- lowing:
acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bucindolol, butoxamine, carteolol, carvedilol, celiprolol, cyanopindolol, esmolol, labetalol, landiolol, levobunolol, methipranolol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, or, if chemically possible, a pharmaceutically acceptable acid addition salt or a metal salt of the active ingredients listed. Preferably, the metoprolol is used in the form of its tartrate or succinate.
A preferred beta-receptor blocking agent is the bisoprolol.
The active ingredient of the pharmaceutical composition used as another component of the pharmaceutical combination according to the invention is a hydroximic-acid derivative of general formula I or a pharmaceutically acceptable acid addition salt thereof.
When Ar is pyridyl, it is 2-, 3- or 4-pyridyl.
In the general formula I, a 5- to 7-membered saturated heterocyclic group containing one ni- trogen atom, formulated in Ri is defined as pyrrolidyl, piperidyl or hexamethyleneimino. Preferably, the pyrrolidyl, piperidyl or hexamethyleneimino group is attached via its nitrogen atom to the carbon atom adjacent to Ri.
The N-oxide of the compound of general formula I as defined in (b) above is understood to mean the N-oxide formed on the nitrogen atom of the pyridyl group according to the meaning of Ar, and / or the N-oxide, which is formed on the nitrogen atom present in the 5-7 membered saturated heterocyclic group according to the meaning of Ri.
Pharmaceutically acceptable acid addition salt is an acid addition salt formed with a pharma- ceutically acceptable inorganic or organic acid, such as hydrochloride, acetate, fumarate, maleate, etc.
The compounds of general formula I contain a C = N double bond structural part and therefore may exist both in form of Z and E geometric isomers. Compounds of general formula I, wherein in the formula A is a group of formula -CH=CH-, may have additional geometric isomers too. Corn- pounds of general formula I generally have a chiral centre as well, so that their optically active iso- mers R and S are also possible. In the description and the claims, any compound of general formula I is understood to include their geometric and/or optical isomers as well and an optional mixture of isomers.
A preferred subgroup (a) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (a) above. A particularly preferred compound in this subgroup is the 0-(3- piperidino-2-hydroxy-l-propyl)-nicotinic acid amidoxime (abbreviated as BGP-15), which is expe- diently used in the form of its dihydrochloride of formula II:
A preferred subgroup (a) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (b) above. A particularly preferred compound in this subgroup is the N-[2- hydroxy-3-(l -piperidinyl)propoxy]pyridine-3-carboximidoyl chloride (bimoclomol)
III or one of its N-oxides, N-[2-hydroxy-3-(l-piperidinyl)-propoxy]-pyridine-l-oxide-3-carboximidoyl chloride (arimoclomol) of formula IV
and a pharmaceutically acceptable acid addition salt of the compound of general formula III or IV.
A preferred subgroup (c) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (c) above. A particularly preferred compound in this subgroup is 5-(piperidin- l-ylmethyl)-3-(pyridin-3-yl)-5,6-dihydro-2H-l,2,4-oxadiazine (iroxanadine)
or a pharmaceutically acceptable acid addition salt thereof.
A preferred subgroup (d) of the compounds of general formula I are those wherein Ar, A, X and R are as defined in (d) above. A particularly preferred compound in this subgroup is the N-[3- (hexamethyleneimino)-2-hydroxypropyl]-cinnamic acid amidoxime of the formula (VI), (di) above (abbreviated as NG-094).
and the 3-styryl-4-[3-(hexamethyleneimino)-2-hydroxypropyl]-A2-l,2,4-oxadiazolin-5-one of for mula VII (d2) above (abbreviated as NG-50)
VII
or a pharmaceutically acceptable acid addition salt thereof.
The hydroximic-acid derivatives of formula I are known compounds.
The amidoxime derivatives of formula I wherein Ar, A, X, and R are as defined in (a) above, may be prepared by the process described in U.S. Patent No. 4,187,220.
The hydroximic-acid derivatives of formula I according to (a) above generally have PARP inhibitory activity. Among them, many of the pharmacological effects of BGP-15 of formula II are known.
From the aforementioned U.S. Pat. No. 5,123,121, the use of the BGP-15 for the treatment of diabetic angiopathy is known.
U.S. Patent No. 6,306,878 relates to a method for protecting the mitochondrial genome and / or mitochondria from damage leading to myopathies and neurodegenerative diseases by administer ing an effective, non-toxic dose of a hydroximic-acid derivative, such as BGP-15, to a patient sus ceptible to such damage.
U.S. Pat. No. 6,458,37lrelates to a formulation containing as active ingredient 0.1-30% of a hydroximic-acid derivative, such as BGP-15 and a carrier, which is capable of reducing the occur rence of light damage caused by UV-B radiation.
U.S. Patent No. 6,884,424 relates to a method for inhibiting actinic keratosis by applying a hydroximic-acid derivative, such as BGP-15, to the affected skin.
U.S. Patent No. 6,451,851 relates to a method for treating a patient suffering from a viral infection by treating the patient with a therapeutically effective amount of a known antiviral agent and a hydroximic-acid derivative such as BGP-15.
U.S. Patent No. 6,440,998 relates to a pharmaceutical composition having a reduced side ef- fect having an antitumor effect comprising cisplatin or carboplatin and a hydroximic-acid derivative such as BGP-15. U.S. Patent No. 6,656,955 relates to a pharmaceutical composition having a reduced side effect having an anticancer effect comprising paclitaxel or docetaxel and a hydroximic-acid de- rivative such as BGP-15. U.S. Patent No. 6,720,337 relates to a pharmaceutical composition having
WO 2020/044067 . . . . . , . PCT/HU2019/000033 a reduced side effect having an anti cancer effect comprising oxaliplatm and a hyaroximic-ac deriv ative such as BGP-15. U.S. Patent No. 6,838,469 relates to a pharmaceutical composition having a reduced side effect having an antitumor effect, comprising pyrimidine derivatives and BGP-15.
PCT Patent Application published under No. WO 00/07580 discloses experimental data on the antidiabetic effect of BGP-15 in the treatment of type 1 diabetes.
PCT Application published under No. WO 03/007951 relates to a pharmaceutical combination of hydroximic-acid derivatives such as BGP-1 and an antidiabetic or antihyperlipidemic agent for the prevention or treatment of pre-diabetes, metabolic X-syndrome or diabetes, and disorders associ ated with these conditions, such as endogenous metabolic disorders, insulin resistance, dyslipidae- mia, baldness, diffuse effluvium, and / or female endocrine disorders based on androgen overweight.
PCT Application published under No. WO 2005/122678 relates to the use of BGP-15 in a pharmaceutical composition having prokinetic activity (i.e., inducing activity in the stomach and in testines).
PCT Application published under No. WO 2005/123049 relates to the use of BGP-15 for mi tochondrial genesis, that is, to increase the number of mitochondria present in cells, resulting in a robotizing effect.
PCT Application published under No. WO 2006/079910 relates to the use of BGP-15 in the treatment of oral cavity lesions, particularly in periodontal disease.
European Patent No. 2,089,031 discloses that BGP-15 can be used to reduce overweight or obesity.
European Patent No. 2,089,032 discloses that BGP-15 reduces the side effects of known anti- psychotics, antidepressants and antiepileptics leading to overweight or obesity.
PCT Patent Application published under No. WO 2009/074835 discloses that BGP-15 can be used to reduce adverse psychiatric side effects of cannabinoid CBi receptor antagonists, such as ri- monabant.
PCT Patent Application published under No. WO 2013/024311 discloses that BGP-15 may be used for the prevention and / or treatment of muscle atrophy.
PCT Patent Application published under No. WO 2013/024312 discloses that BGP-15 can be used to improve the tissue regeneration effect of adult stem cells, to promote the survival, adhesion, and regulation of adult stem cells.
The bimoclomol of formula III according to (b) above is described in International Patent Application published under No. WO 90/04584. According to the description the bimoclomol appli cable in the treatment of diabetic angiopathy can be prepared by reacting 3-pyridyl aldoxime with 3-
piperidino-2-hydroxy-l-chloropropane, then by the chlorination of the obtained 0-(3-piperidino-2- hydroxy-l -propyl) with thionyl chloride.
International Patent Application published under No. WO 97/16439 discloses that the expres- sion or activity of molecular chaperones is enhanced by the use of various compounds, including bimoclomol. Based on the mechanism of action described, the compound may be used in the treat- ment of pathological conditions related to cell membranes or cellular organelles such as diabetes mellitus, diseases associated with mitochondrial damage, diseases of toxic origin, cardiovascular, vascular, allergic diseases, immune and autoimmune diseases, viral infections, bacterial infections, tumorous diseases, skin diseases, diseases caused by physiological stress.
International Patent Application published under No. WO 00/50403 discloses arimoclomol of formula IV, its stereoisomers and its use in the treatment of insulin resistance and related pathological conditions. The industrially applicable preparation of the latter compound and its stereoisomers is described in International Patent Application Publication No. WO 01/79174.
International Patent Application published under No. WO 2005/041965 discloses the use of arimoclomol or its optical isomers in the treatment of neurodegenerative diseases. The anteriority does not include comparative test data to compare the pharmacological activity of the optically active enantiomers with that of the racemic compound.
International Patent Application published under No. WO 2008/137149 discloses that bimoclomol and arimoclomol promote wound healing in diabetic patients.
International Patent Application published under No. WO 2008/070010 discloses that bimo- clomol and arimoclomol can be used to treat stroke.
International Patent Application published under No. WO 2009/155936 discloses that bimo- clomol and arimoclomol can be used to increase the intracellular concentration and / or activity of Hsp 70 in a lysosomal storage disease, such as for the treatment of Niemann-Pick disease, Gaucher disease, Farber disease, Rrabbe disease, Fabbre disease, or sialidosis.
International Patent Application published under No. WO 2013/045962 discloses the use of bimoclomol and arimoclomol for the prevention and / or treatment of muscle atrophy, e.g. muscle dystrophy in long-term akinesia.
According to International Patent Application published under No. WO 2013/045963, bimo- clomol and arimoclomol can be used to improve the tissue regeneration effect of adult stem cells, to promote stem cell survival, adhesion and differentiation.
The hydroxy acid derivatives of formula I according to (c) above are known from European Patent Application No. EP 801 649.
Hungarian patent applications P 98 02896 and P 98 02897, published on November 28, 2000, disclose the (+) - and (-) - enantiomer of iroxanadine of formula V. The enantiomers are useful in the treatment of vascular diseases
The hydroxy acid derivatives of formula I according to (d) above may be prepared according to the methods described in PCT Application Published under No. WO 01/70674. The compounds are useful in the treatment of conditions deficient in oxygen and / or energy, diseases based on PARP inhibition, diseases of viral origin or diseases caused by toxic effects. The compounds are also disclosed in the aforementioned PCT Patent Applications published under Nos. WO 2013/02431 1 and WO 2013/024312.
The pharmaceutical combination according to the invention is understood to mean the follow- ing compositions:
a combination of the separate pharmaceutical composition comprising the beta-receptor blocking agent and a pharmaceutically acceptable carrier and the separate pharmaceutical composi- tion comprising the hydroximic-acid derivative of formula I and a pharmaceutically acceptable car rier, wherein each separate pharmaceutical composition is administered simultaneously or sequen tially to the patient who is in need of the treatment; or
a pharmaceutical composition comprising the beta-blocking agent and a hydroximic-acid de rivative of formula I and a pharmaceutically acceptable carrier at the same time, wherein either a mixture of the two agents is present, or each is present in a different location in the pharmaceutical composition, e.g. in the tablet core and the other in the tablet core coating.
Of course, any conventional carrier and any conventional pharmaceutical preparation proce dure may be used to prepare the individual pharmaceutical compositions or the single pharmaceutical composition.
The pharmaceutical combination may be any dosage form suitable for oral, parenteral or rectal administration or topical administration, or solid or liquid form. The weight ratio of active ingredients in the pharmaceutical combination is generally (1-1000) : ( 1000- 1 ) .
In principle, the pharmaceutical combination of the invention may contain more than one beta- receptor blocking agent.
Solid pharmaceutical compositions suitable for oral administration may be in the form of powders, capsules, tablets, film-coated tablets, microcapsules, sustained-release formulations, etc., and may contain binding agents as carriers, such as gelatine, sorbitol, polyvinylpyrrolidone, etc.; fillers such as lactose, glucose, starch, calcium phosphate, etc.; tabletting aids such as magnesium stearate, talc, polyethylene glycol, silica, etc.; wetting agents such as sodium lauryl sulphate, etc.
Liquid pharmaceutical preparations for oral administration may be in the form of solutions, suspensions or emulsions and may include as carriers, for example, suspending agents, such as gela- tine, carboxymethylcellulose, etc.; emulsifiers such as sorbitan monooleate, etc.; solvents such as water, oils, glycerol, propylene glycol, ethanol, etc.; preservatives such as methyl p-hydroxybenzoic acid, etc.
Pharmaceutical compositions for parenteral administration are generally sterile solutions of the active compounds.
The above dosage forms and other dosage forms are known per se, see, for example, Reming- ton's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., Easton, USA (1990).
The drug combination will generally contain a unit dose of the active ingredients. The daily dose may be administered in one or more portions. The actual dose will depend on many factors and will be determined by the doctor.
The pharmaceutical composition (s) forming the pharmaceutical combination of the present invention may be prepared in a manner known in the art (e.g., Remington's Pharmaceutical Sciences mentioned above).
The present invention relates to the use of a hydroximic-acid derivative of the Formula I or a pharmaceutically acceptable acid addition salt thereof for reducing one or more side effects of a beta- receptor blocking drug, wherein the side effects include particularly cardiovascular side effects such as bradycardia, hypotension, heart failure, cardiac arrest, dizziness, muscle weakness, fatigue, periph eral vasoconstrictor effect, etc. or aggravation of asthma.
Accordingly, to a patient treated with a pharmaceutical preparation having a beta-receptor blocking active ingredient is administered also a hydroximic-acid derivative of formula I or a phar maceutically acceptable acid addition salt thereof, preferably in the form of a pharmaceutical prepa ration. The two active substances may be administered simultaneously or sequentially. For administration, the active ingredient may be present in separate pharmaceutical preparations or in a single pharmaceutical preparation, as described above.
Claims
1. Pharmaceutical preparation having reduced side effect, comprising a first pharmaceu- tical preparation comprising a beta-blocker as an active ingredient and a second pharmaceutical prep aration containing as an active ingredient a hydroximic-acid derivative of the general formula I
X
I
Ar— A— C=N— R
or a pharmaceutically acceptable acid addition salt thereof, wherein in general formula I a) Ar is pyridyl,
A is a valence bond,
X is -NH2,
R is a group of the general formula
OH
— O— CH2— CH— CH2— Ri wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or b) Ar is pyridyl,
A is a valence bond,
X is -halogen,
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or its N- oxide, or
c) Ar is pyridyl,
A is a valence bond,
X is a group of the general formula
Y
-NH— O— CH2— CH— CH2— Ri
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom,
R taken together with Y form a valence bond between the nitrogen adjacent to R and the carbon adjacent to Y to form a six -membered oxadiazine ring, or
d) Ar is phenyl,
A is -CH = CH- and
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom,
R is a hydroxyl group, or
d2) X is a group of the general fonnula
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, Y’ taken together with R form a valence bond between the oxygen adjacent to Y’ and the nitrogen adjacent to R this way forms a five-membered l,2,4-oxadiazoline ring.
2. The pharmaceutical combination of claim 1, which modifies the pharmacological ef fect of beta-receptor blockers, results in novel pharmacological effects, including regulation of the functioning of hyperpolarization- activated cyclic nucleotide-gated channels (If channels).
3. The pharmaceutical combination of claim 1 , wherein the beta-receptor blocking active ingredient and the hydroximic-acid derivative of the formula I or a pharmaceutically acceptable acid addition salt thereof are contained in one common pharmaceutical composition with one or more commonly used carriers.
4. The pharmaceutical combination according to claim 1 or 2, wherein the beta-receptor blocking agent is selected from the group consisting of acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, methipranolol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, or, if desired, a pharmaceutically acceptable acid addition salt or metal salt thereof.
5. The pharmaceutical combination of claim 3, wherein the beta receptor blocking agent is bisoprolol.
6. The pharmaceutical combination of claim 1 or 2, containing 0-(3-piperidino-2-hy- droxy-l-propyl)-nicotinic acid amidoxime dihydrochloride of the fonnula II
as a hydroximic-acid derivative of the formula I.
WO 2020/044067 . , . . . , . _ , · , , PCT/HTI2019/000033
7. t he pharmaceutical combination of claim 1 or 2, wherein the hyuiu un^-a^ u um»- ative of the formula I is the N-[2-hydroxy-3-(l-piperidinyl)-propoxy]-pyridine-3-carboximidoyl chloride of formula III,
8. The pharmaceutical combination of claim 1 or 2, wherein the hydroximic-acid deriv ative of formula I is 5-(piperidin-l-ylmethyl)-3-(pyridin-3-yl)-5,6-dihydro-2H-l,2,4-oxadiazine of formula V,
or a pharmaceutically acceptable acid addition salt thereof.
9. The pharmaceutical combination of claim 1 or 2, wherein the hydroximic-acid deriv- ative of formula I is the N-[3-(hexamethyleneimino)-2-hydroxypropyl] cinnamic acid amidoxime of formula VI,
or a pharmaceutically acceptable acid addition salt thereof.
10. The pharmaceutical combination of claim 1 or 2, wherein the hydroximic-acid derivative of formula I is the 3-styryl-4-[3-(hexamethyleneimino)-2-(hydroxypropyl)-A2-l,2,4-oxadia- zolin-5-one amidoxime of formula VII,
VII
or a pharmaceutically acceptable acid addition salt thereof.
11. The hydroximic-acid derivative of the general formula I
X
Ar— A— C=N— R
or a pharmaceutically acceptable acid addition salt thereof, wherein in general formula I
a) Ar is pyridyl,
A is a valence bond,
X is -NH2,
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or b) Ar is pyridyl,
A is a valence bond,
X is -halogen,
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, or its N- oxide, or
c) Ar is pyridyl,
A is a valence bond,
X is a group of the general formula
Y
-NH— O— CH2— CH— CH2— Ri
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom,
R taken together with Y form a valence bond between the nitrogen adjacent to R and the carbon adjacent to Y this way forms a six-membered oxadiazine ring, or
d) Ar is phenyl,
A is -CH = CH- and
di) X is a group of the general formula
Y
-NH— CH2— CH— CH2— Ri
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom,
R is a hydroxyl group, or
d2) X is a group of the general formula
wherein Ri is a 5-7 membered saturated heterocyclic group containing one nitrogen atom, Y’ taken together with R form a valence bond between the oxygen adjacent to Y’ and the nitrogen adjacent to R this way forms a five-membered 1,2,4-oxadiazoline ring, or a pharmaceutically acceptable acid addition salt thereof for use in reducing one or more side effects of a beta receptor blocking drug, wherein the side effects include, in particular, cardiovascular side effects such as bradycardia, hypo tension, heart failure, cardiac arrest, dizziness, muscle weakness, fatigue, peripheral vasoconstrictor effects, and the like, or worsening of asthma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1800298A HUP1800298A1 (en) | 2018-08-30 | 2018-08-30 | Combination of beta blocker and hydroximic acid derivative with reduced side effects |
HUP1800298 | 2018-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020044067A1 true WO2020044067A1 (en) | 2020-03-05 |
Family
ID=89992747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2019/000033 WO2020044067A1 (en) | 2018-08-30 | 2019-10-30 | Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects |
Country Status (2)
Country | Link |
---|---|
HU (1) | HUP1800298A1 (en) |
WO (1) | WO2020044067A1 (en) |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4187220A (en) | 1977-08-30 | 1980-02-05 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
WO1990004584A1 (en) | 1988-10-20 | 1990-05-03 | Biorex Kutató Fejleszto^' Kft. | Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same |
US5123121A (en) | 1988-03-07 | 1992-06-23 | Bell Helmets, Inc. | Helmet retention system with adjustable buckle |
WO1997016439A1 (en) | 1995-11-02 | 1997-05-09 | Biorex Kutató és Fejlesztó Rt. | Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof |
WO2000007580A2 (en) | 1998-08-03 | 2000-02-17 | N-Gene Kutató Kft. | Pharmaceutical compositions against autoimmune diseases |
WO2000050403A1 (en) | 1999-02-26 | 2000-08-31 | BIOREX Kutató és Fejlesztő Rt. | N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance |
WO2001070674A1 (en) | 2000-03-20 | 2001-09-27 | N-Gene Research Laboratories Inc. | Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
US6306878B1 (en) | 1995-09-29 | 2001-10-23 | N-Gene Research Lab Inc | Pharmaceutical compositions containing hydroximic acid derivatives |
WO2001079174A1 (en) | 2000-04-18 | 2001-10-25 | BIOREX Kutató és Fejlesztő Rt. | A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds |
US6440998B1 (en) | 1997-06-23 | 2002-08-27 | N-Gene Research Laboratories, Inc. | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative |
US6451851B1 (en) | 1997-06-23 | 2002-09-17 | N-Gene Research Laboratories Inc. | Pharmaceutical composition with antiviral activity containing an hydroxymic acid derivative and an antiviral agent |
US6458371B1 (en) | 1995-12-22 | 2002-10-01 | Medgene, Limited | Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin |
WO2003007951A1 (en) | 2001-07-17 | 2003-01-30 | N-Gene Research Laboratories Inc. | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
US6884424B2 (en) | 1995-12-22 | 2005-04-26 | N-Gene Research Laboratories Inc. | Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight |
WO2005041965A1 (en) | 2003-10-30 | 2005-05-12 | Cytrx Corporation | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
WO2005122678A2 (en) | 2004-06-14 | 2005-12-29 | N-Gene Research Laboratories Inc. | A pharmaceutical composition having prokinetic effect and comprising o-(3-piperidino-2-hydroxypropyl) nicotinic amidoxime |
WO2005123049A2 (en) | 2004-06-14 | 2005-12-29 | N-Gene Research Laboratories Inc. | A pharmaceutical composition for increasing the mitochondrial genesis |
WO2006079910A2 (en) | 2005-01-28 | 2006-08-03 | N-Gene Research Laboratories Inc. | 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity |
WO2008070010A2 (en) | 2006-12-01 | 2008-06-12 | Cytrx Corporation | Hydroxylamine derivatives for the treatment of stroke |
WO2008137149A1 (en) | 2007-05-04 | 2008-11-13 | Cytrx Corporation | Diabetic wound healing |
WO2009074835A1 (en) | 2007-12-10 | 2009-06-18 | N-Gene Research Laboratories Inc. | Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity |
EP2089032A1 (en) | 2006-11-02 | 2009-08-19 | N-Gene Research Laboratories Inc. | A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect |
EP2089031A1 (en) | 2006-11-02 | 2009-08-19 | N-Gene Research Laboratories Inc. | Reduction of overweight or obesity |
WO2009155936A1 (en) | 2008-06-26 | 2009-12-30 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
WO2013024311A1 (en) | 2011-08-17 | 2013-02-21 | Pharma-Gene Sa | Amidoxime derivatives for the prevention and/or treatment of muscle atrophy |
WO2013024312A1 (en) | 2011-08-17 | 2013-02-21 | Pharma-Gene Sa | A pharmaceutical composition for the treatment of stem cells |
WO2013045962A1 (en) | 2011-09-26 | 2013-04-04 | Hazay Balazs | Pharmaceutical composition for the prevention and/or treatment of muscle atrophy |
WO2013045963A1 (en) | 2011-09-26 | 2013-04-04 | Hazay Balazs | A pharmaceutical composition for the treatment of stem cells |
WO2014138814A1 (en) * | 2013-03-14 | 2014-09-18 | Coats Andrew J S | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis |
-
2018
- 2018-08-30 HU HU1800298A patent/HUP1800298A1/en unknown
-
2019
- 2019-10-30 WO PCT/HU2019/000033 patent/WO2020044067A1/en active Application Filing
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4187220A (en) | 1977-08-30 | 1980-02-05 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
US5123121A (en) | 1988-03-07 | 1992-06-23 | Bell Helmets, Inc. | Helmet retention system with adjustable buckle |
WO1990004584A1 (en) | 1988-10-20 | 1990-05-03 | Biorex Kutató Fejleszto^' Kft. | Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same |
US6306878B1 (en) | 1995-09-29 | 2001-10-23 | N-Gene Research Lab Inc | Pharmaceutical compositions containing hydroximic acid derivatives |
WO1997016439A1 (en) | 1995-11-02 | 1997-05-09 | Biorex Kutató és Fejlesztó Rt. | Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof |
EP0801649A2 (en) | 1995-11-02 | 1997-10-22 | Biorex Kutato Es Fejlesztö Rt. | Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof |
US6884424B2 (en) | 1995-12-22 | 2005-04-26 | N-Gene Research Laboratories Inc. | Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight |
US6458371B1 (en) | 1995-12-22 | 2002-10-01 | Medgene, Limited | Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin |
US6838469B2 (en) | 1997-06-23 | 2005-01-04 | N-Gene Research Laboratories Inc. | Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity |
US6440998B1 (en) | 1997-06-23 | 2002-08-27 | N-Gene Research Laboratories, Inc. | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative |
US6451851B1 (en) | 1997-06-23 | 2002-09-17 | N-Gene Research Laboratories Inc. | Pharmaceutical composition with antiviral activity containing an hydroxymic acid derivative and an antiviral agent |
US6656955B2 (en) | 1997-06-23 | 2003-12-02 | N-Gene Research Laboratories, Inc. | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative |
US6720337B2 (en) | 1997-06-23 | 2004-04-13 | N-Gene Research Laboratories, Inc. | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxlmic acid derivative |
WO2000007580A2 (en) | 1998-08-03 | 2000-02-17 | N-Gene Kutató Kft. | Pharmaceutical compositions against autoimmune diseases |
WO2000050403A1 (en) | 1999-02-26 | 2000-08-31 | BIOREX Kutató és Fejlesztő Rt. | N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance |
WO2001070674A1 (en) | 2000-03-20 | 2001-09-27 | N-Gene Research Laboratories Inc. | Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
WO2001079174A1 (en) | 2000-04-18 | 2001-10-25 | BIOREX Kutató és Fejlesztő Rt. | A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds |
WO2003007951A1 (en) | 2001-07-17 | 2003-01-30 | N-Gene Research Laboratories Inc. | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
WO2005041965A1 (en) | 2003-10-30 | 2005-05-12 | Cytrx Corporation | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
WO2005122678A2 (en) | 2004-06-14 | 2005-12-29 | N-Gene Research Laboratories Inc. | A pharmaceutical composition having prokinetic effect and comprising o-(3-piperidino-2-hydroxypropyl) nicotinic amidoxime |
WO2005123049A2 (en) | 2004-06-14 | 2005-12-29 | N-Gene Research Laboratories Inc. | A pharmaceutical composition for increasing the mitochondrial genesis |
WO2006079910A2 (en) | 2005-01-28 | 2006-08-03 | N-Gene Research Laboratories Inc. | 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity |
EP2089032A1 (en) | 2006-11-02 | 2009-08-19 | N-Gene Research Laboratories Inc. | A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect |
EP2089031A1 (en) | 2006-11-02 | 2009-08-19 | N-Gene Research Laboratories Inc. | Reduction of overweight or obesity |
WO2008070010A2 (en) | 2006-12-01 | 2008-06-12 | Cytrx Corporation | Hydroxylamine derivatives for the treatment of stroke |
WO2008137149A1 (en) | 2007-05-04 | 2008-11-13 | Cytrx Corporation | Diabetic wound healing |
WO2009074835A1 (en) | 2007-12-10 | 2009-06-18 | N-Gene Research Laboratories Inc. | Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity |
WO2009155936A1 (en) | 2008-06-26 | 2009-12-30 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
WO2013024311A1 (en) | 2011-08-17 | 2013-02-21 | Pharma-Gene Sa | Amidoxime derivatives for the prevention and/or treatment of muscle atrophy |
WO2013024312A1 (en) | 2011-08-17 | 2013-02-21 | Pharma-Gene Sa | A pharmaceutical composition for the treatment of stem cells |
WO2013045962A1 (en) | 2011-09-26 | 2013-04-04 | Hazay Balazs | Pharmaceutical composition for the prevention and/or treatment of muscle atrophy |
WO2013045963A1 (en) | 2011-09-26 | 2013-04-04 | Hazay Balazs | A pharmaceutical composition for the treatment of stem cells |
WO2014138814A1 (en) * | 2013-03-14 | 2014-09-18 | Coats Andrew J S | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis |
Non-Patent Citations (2)
Title |
---|
"Reming-ton's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
FRISHMAN, W.H.: "beta-Adrenergic blockers: a 50-year hysterical perspective", AM. J. THER., vol. 15, no. 6, 2008, pages 565 - 76 |
Also Published As
Publication number | Publication date |
---|---|
HUP1800298A1 (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1919477B1 (en) | Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders | |
WO2013109972A2 (en) | Therapeutic compounds | |
US20230062049A1 (en) | Methods of treating alpha adrenergic mediated conditions | |
BRPI0720664A2 (en) | ISOSORBID MONONITRATE DERIVATIVES FOR EYE HYPERTENSION TREATMENT. | |
JP2834328B2 (en) | Cancer treatment | |
EP2303264B1 (en) | Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives | |
US11571411B2 (en) | Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals | |
WO2020044067A1 (en) | Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects | |
CA2241856C (en) | Agent for prophylaxis and treatment of diabetic complications | |
AU7730501A (en) | Prophylactic use of N-methyl-D-aspartate (NMDA) antagonists | |
MXPA02001740A (en) | Use of bis sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia. | |
KR20060125862A (en) | Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency | |
WO2009152053A1 (en) | Methods of treating alpha adrenergic mediated conditions using imidazoline derivates | |
EP0694299A1 (en) | The use of( a) bicycloheptane derivative(s) | |
US8106099B2 (en) | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | |
CZ200380A3 (en) | Compounds treating disorders connected with dependences | |
US20050054673A1 (en) | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | |
WO2003084482A2 (en) | Antidepressants and their analogues as long-acting local anesthetics and analgesics | |
KR20070104913A (en) | Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes | |
US4388320A (en) | 3-Aminopropoxyaryl derivative in the treatment of tremor | |
RU2021108172A (en) | PHARMACEUTICAL COMBINATION FOR CHANGING THE ACTION OF BETA-RECEPTOR BLOCKERS AND REDUCING SIDE EFFECTS | |
WO2021246455A1 (en) | Antifungal agent for use in humans | |
KR20050106120A (en) | Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin | |
JP2024508498A (en) | Combination of Reboxetine and Muscarinic Receptor Antagonist (MRA) for Use in the Treatment of Sleep Apnea | |
CA2538009A1 (en) | Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19808872 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19808872 Country of ref document: EP Kind code of ref document: A1 |